Ginkgo Bioworks Holdings Inc - Class A
Research Ginkgo Bioworks Holdings Inc - Class A (DNA) on Bullrun: market cap USD 457.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDNA
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 457.76M
- Financial periodQ2 2026
- RevenueUSD 20.16M
- Net income-USD 46.71M
- Free cash flow-USD 46.89M
- Gross margin91.5%
Valuation Snapshot
latest market cap is USD 457.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 170.16M | -USD 313.00K | -USD 178.72M | 72.4% | -5.64 | USD 167.20M | USD 439.89M | USD 508.59M |
| FY2024 | USD 227.04M | -USD 547.00K | -USD 382.13M | 80.4% | -10.54 | USD 561.57M | USD 467.73M | USD 716.06M |
| FY2023 | USD 251.46M | -USD 893.00K | -USD 336.30M | n/a | -18.37 | USD 944.07M | USD 239.31M | USD 1.10B |
| FY2022 | USD 477.71M | -USD 2.11M | -USD 304.47M | n/a | -50.2 | USD 1.32B | USD 51.55M | USD 1.74B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 457.76M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 483.70M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 533.87M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.58B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.35B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 13.39B | n/a | n/a | n/a |
About Ginkgo Bioworks Holdings Inc - Class A
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ginkgo Bioworks Holdings Inc - Class A's market cap?
Ginkgo Bioworks Holdings Inc - Class A's market capitalization is USD 457.76M.
What does Ginkgo Bioworks Holdings Inc - Class A do?
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.